Cysteine protease
The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
1. A polypeptide having IgG cysteine protease activity and comprising a variant of the sequence of SEQ ID NO:2, which variant:
(a) is at least 80% identical to SEQ ID NO: 7;
(b) has a cysteine (C) at the position in said variant sequence which corresponds to position 94 of SEQ ID NO: 1; and
(c) has, at the positions in said variant sequence which correspond to positions 84, 262, 284 and 286 of SEQ ID NO: 1, a lysine (K), a histidine (H), an aspartic acid (D) and an aspartic acid (D), respectively;
wherein said polypeptide is more effective at cleaving IgG than IdeS and/or is less immunogenic than IdeS, and wherein said variant of the sequence of SEQ ID NO: 2 comprises a substitution made at one or more of the positions
corresponding to positions 115, 119, 139, 142, 198, 216, 226, 241, 245, 302, 316, and 333 of SEQ ID NO: 1.
2. The polypeptide according to claim 1 , wherein said variant of the sequence of SEQ ID NO: 2 is at least 90%, 95% or 99% identical to SEQ ID NO: 7.
3. The polypeptide according to claim 1 , wherein said sequence includes an additional methionine at the N terminus and/or a histidine tag at the C terminus.
4. The polypeptide according to claim 1 , wherein said polypeptide is at least 1.5 fold, 2.0 fold, 2.5 fold, 3.0 fold, 4.0 fold, 4.5 fold, 5.0 fold, 6.0 fold, 7.0 fold or 7.5 fold greater more effective than IdeS at cleaving IgG, when measured in the same assay.
5. The polypeptide according to claim 1 which is less immunogenic than IdeS, wherein preferably the immunogenicity of said polypeptide is no more than 85% of the immunogenicity of IdeS when measured in the same assay.